180 related articles for article (PubMed ID: 32838518)
1. Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Muhammad N; Tan CP; Nawaz U; Wang J; Wang FX; Nasreen S; Ji LN; Mao ZW
Inorg Chem; 2020 Sep; 59(17):12632-12642. PubMed ID: 32838518
[TBL] [Abstract][Full Text] [Related]
2. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
3. Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum
Muhammad N; Cai-Ping T; Nasreen S; Mao ZW
Chem Asian J; 2021 Aug; 16(16):2276-2279. PubMed ID: 34231967
[TBL] [Abstract][Full Text] [Related]
4. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
[TBL] [Abstract][Full Text] [Related]
5. A novel star-shaped trinuclear platinum(II) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism.
Wu Y; Zhao D; Shang J; Huang W; Chen Z
Dalton Trans; 2022 Jul; 51(29):10930-10942. PubMed ID: 35731536
[TBL] [Abstract][Full Text] [Related]
6. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.
Chen H; Chen F; Hu W; Gou S
J Inorg Biochem; 2018 Mar; 180():119-128. PubMed ID: 29253663
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria-targeted Pt(IV) prodrugs conjugated with an aggregation-induced emission luminogen against breast cancer cells by dual modulation of apoptosis and autophagy inhibition.
Su Y; Tu Y; Lin H; Wang MM; Zhang GD; Yang J; Liu HK; Su Z
J Inorg Biochem; 2022 Jan; 226():111653. PubMed ID: 34740039
[TBL] [Abstract][Full Text] [Related]
8. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
9. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
10. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
11. Mitochondria-targeted ruthenium complexes can be generated in vitro and in living cells to target triple-negative breast cancer cells by autophagy inhibition.
Zhang GD; Wang MM; Su Y; Fang H; Xue XL; Liu HK; Su Z
J Inorg Biochem; 2024 Jul; 256():112574. PubMed ID: 38677004
[TBL] [Abstract][Full Text] [Related]
12. CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors.
Cao Q; Zhou DJ; Pan ZY; Yang GG; Zhang H; Ji LN; Mao ZW
Angew Chem Int Ed Engl; 2020 Oct; 59(42):18556-18562. PubMed ID: 32557982
[TBL] [Abstract][Full Text] [Related]
13. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells.
Hong Y; Fan D
Toxicology; 2019 Apr; 418():22-31. PubMed ID: 30797898
[TBL] [Abstract][Full Text] [Related]
15. Myricetin-induced apoptosis of triple-negative breast cancer cells is mediated by the iron-dependent generation of reactive oxygen species from hydrogen peroxide.
Knickle A; Fernando W; Greenshields AL; Rupasinghe HPV; Hoskin DW
Food Chem Toxicol; 2018 Aug; 118():154-167. PubMed ID: 29742465
[TBL] [Abstract][Full Text] [Related]
16. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
17. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
18. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
Roy A; Ahir M; Bhattacharya S; Parida PK; Adhikary A; Jana K; Ray M
Mol Carcinog; 2017 Sep; 56(9):2086-2103. PubMed ID: 28418078
[TBL] [Abstract][Full Text] [Related]
19. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
20. A targeted theranostic platinum(IV) prodrug containing a luminogen with aggregation-induced emission (AIE) characteristics for in situ monitoring of drug activation.
Yuan Y; Chen Y; Tang BZ; Liu B
Chem Commun (Camb); 2014 Apr; 50(29):3868-70. PubMed ID: 24589580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
